Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study.

[1]  Yibo Gao,et al.  Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. , 2021, The Lancet. Oncology.

[2]  Douglas B. Johnson,et al.  Cutaneous adverse events caused by immune checkpoint inhibitors. , 2021, Journal of the American Academy of Dermatology.

[3]  Xiaoling Chen,et al.  Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China , 2021, Frontiers in Oncology.

[4]  M. Altan,et al.  Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy. , 2021, Clinical lung cancer.

[5]  R. Gniadecki,et al.  Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management , 2020, Journal of cutaneous medicine and surgery.

[6]  Hui Zhu,et al.  PD-1 inhibitor plus chemotherapy as 2nd/subsequent line therapy had similar clinical outcome with PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC. , 2020 .

[7]  G. Damiani,et al.  Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. , 2020, Critical reviews in oncology/hematology.

[8]  W. Fang,et al.  Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial , 2020, Journal of Hematology & Oncology.

[9]  Matthew J. Frigault,et al.  NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  D. Maucort-Boulch,et al.  Cutaneous adverse events: a predictor of tumour response under anti‐PD‐1 therapy for metastatic melanoma, a cohort analysis of 189 patients , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  Yi Yang,et al.  Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis , 2020, Frontiers in Pharmacology.

[12]  A. Cope,et al.  Mechanisms of checkpoint inhibition‐induced adverse events , 2020, Clinical and experimental immunology.

[13]  Yuan-jun Teng,et al.  Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials , 2020, Frontiers in Pharmacology.

[14]  G. Bregni,et al.  PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. , 2020, Cancer letters.

[15]  J. Sugisaka,et al.  Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. , 2019, The oncologist.

[16]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[17]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[18]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[19]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[20]  K. Chamoto,et al.  Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy , 2018, Journal of internal medicine.

[21]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[22]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[25]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[26]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[27]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[28]  A. Daud,et al.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. , 2015, JAMA dermatology.

[29]  A. Amin,et al.  Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. , 2015, Translational lung cancer research.